Dr. Katja Weisel on the GMMG-CONCEPT Trial

What is the background of the study?

As high-risk (HR) multiple myeloma (MM) patients (pts) still have a significantly impaired prognostic outcome, there is an unmet clinical need for potent therapeutic strategies already in front-line therapy for newly diagnosed (ND) MM, leading to improvement of long-term survival. Ultra-high-risk patients with ≥ 3 HR cytogenetic aberrations (CA) have a median overall survival (OS) of less than 2 years. Recent data indicate that achievement of deep remissions, including negativity for minimal residual disease (MRD) may translate into prolonged progression-free (PFS) and OS. 

In this video:

Dr. Katja Weisel (Universitätsklinikum Hamburg-Eppendorf,Hamburg, Germany) discusses the GMMG-CONCEPT Trial investigating Isa-KRd in frontline treatment of high-risk multiple myeloma.

Conclusions:

With a best overall response rate of 100% during quadruplet induction treatment, we here report an update of the IA for PFS of the first 50 patients in the CONCEPT trial. In these solely high-risk, newly diagnosed multiple myeloma patients an encouraging PFS rate of 79.6% and 75.5% after 12- and 24-months is reported. Our data underline the high potency of quadruplet treatment with Isa-KRd especially in patients with HR disease. The study completed recruitment, further results will be reported.